EU consultation frames the next GMP controls for digital systems and AI
Draft revisions to Chapter 4 and Annex 11, plus a proposed Annex 22 for artificial intelligence, signal the direction of travel—but remain consultation drafts rather than operative requirements.
Editorial figure by RegQuality Review. Source context: European Commission Directorate-General for Health and Food Safety.
The drafts expand lifecycle expectations
The consultation summary emphasizes risk management, data governance, records across formats, supplier oversight, audit trails, electronic signatures, security, intended use, model performance, training data, change control, monitoring, and human review. Together, those themes point toward more explicit governance for digital systems used in pharmaceutical manufacturing.
They are relevant to planning, but they are not final law or guidance. Organizations should distinguish a gap assessment against draft language from a formal compliance action against current GMP. That distinction should remain visible in project charters and vendor requirements.
AI claims need a controlled intended use
The proposed Annex 22 focuses on model selection, training, validation, performance, data, ongoing oversight, and human review. Those topics cannot be evaluated through a generic AI-enabled badge. The same model may present different quality risk when used to retrieve a procedure, recommend a classification, draft a record, or make an automated manufacturing decision.
Buyers should ask providers to identify each model, purpose, data path, decision boundary, monitoring method, change process, and fallback. They should also ask which claims depend on a future product or a future regulatory text.
How the market record should label the event
A change ledger should mark this as a closed consultation milestone, not a final standard. It should retain links to the draft texts, note the existing applicable documents, and monitor the Commission's EudraLex page for adoption or revision.
RegQuality Review will maintain separate status fields for draft, consultation, adopted, effective, and superseded material. This reduces the risk that search-oriented summaries convert a proposal into a current requirement.
Enterprise buyer test
Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.
A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.
What we will watch next
RegQuality Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.